18F‐FDG‐PET/CT imaging in diagnostic workup of pediatric precursor B‐cell lymphoblastic lymphoma
Emma Kroeze, Laura Arias Padilla, Birgit Burkhardt, Andishe Attarbaschi, Hannah von Mersi, Rejin Kebudi, Rutger A. J. Nievelstein, Nelleke Tolboom, Melanie M Hagleitner, Roland P Kuiper, Auke Beishuizen, Jan L. C. Loeffen- Oncology
- Hematology
- Pediatrics, Perinatology and Child Health
Abstract
18F‐fluorodeoxyglucose‐positron emission tomography/computed tomography (PET/CT) imaging is currently not used in standard diagnostics for B‐cell precursor lymphoblastic lymphoma (BCP‐LBL), and it is unknown whether PET/CT imaging would lead to agreement between detection of lesions with the gold standard imaging methods. Therefore, we performed a retrospective cohort study in which we included 32 pediatric BCP‐LBL patients and determined localizations by reviewing local imaging reports. There was a disagreement between protocol‐based imaging and PET/CT in 59% of the patients, and the discrepancies mostly comprise of additional lesions detected with PET/CT, typically in lymph node and bone or the absence of bone marrow involvement with PET/CT. If PET/CT was leading in determining definite stage of disease, this would lead to a different stage and therapy branch in 31% and 28% of the patients, respectively.